The majority of oncology drugs (70 percent) will be high-cost orphan drugs–focused on relatively small group of patients with rare subsets of cancer. (Photo: Shutterstock)
A new report says the FDA will evaluate more than 150 new drugs for approval in 2020, with 11 drugs representing potential blockbuster sales of more than $1 billion each.
The report from OptumRx, the pharmacy benefits manager for UnitedHealth Group, said that 64 of the new drugs already have anticipated approval dates this year. The company monitors the drug development pipeline in the U.S., with an eye for what drugs will likely have the biggest impact in terms of quality, cost, and effectiveness.
Drug trends—oncology drugs dominate new releases
The report predicted that oncology drugs will have the most releases by far—44 new oncology drugs are expected to be approved. The next highest category is neurology drugs, at 29 expected approvals.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
